VLX-1005

VLX-1005 is a novel, first-in-class small molecule inhibitor of platelet-type 12-lipoxygenase (12-LOX), developed for the treatment and prevention of thrombosis in patients with heparin-induced thrombocytopenia (HIT). By selectively inhibiting the 12-lipoxygenase pathway, VLX-1005 blocks platelet activation and aggregation mediated by Fc gamma receptor IIa (FcgRIIa; CD32a), which plays a central role in immune-mediated thrombosis such as HIT. The drug has demonstrated efficacy in animal models by preventing or treating HIT and reducing both thrombocytopenia and abnormal blood clot formation without increasing bleeding risk. It is currently being evaluated in Phase II clinical trials for HIT and has received Orphan Drug Designation from both the FDA and EMA. Veralox Therapeutics is developing this agent as its lead candidate[1][3][4][5][6][8].

Other names

1532593-30-8JKU4XCC48YJKU-4XCC48YJKU 4XCC48YN-(1,3-benzothiazol-2-yl)-4-[(2-hydroxy-3-methoxyphenyl)methylamino]benzenesulfonamide